RVMD
What one share of Revolution Medicines holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
Revolution Medicines’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$8.92 |
|---|---|
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$6.22 |
| Cash and investments | $18.38 |
| Debt | $2.28 |
| Book value | $12.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $8.77 | −$21.24 | $0.65 | −$0.12 | — | −$47.16 |
| 2019 | $18.05 | −$22.33 | $0.93 | −$18.83 | — | −$46.35 |
| 2020 | $0.78 | −$2.01 | $0.05 | −$1.88 | — | $7.13 |
| 2021 | $0.40 | −$2.57 | $0.09 | −$2.11 | — | $8.13 |
| 2022 | $0.44 | −$3.08 | $0.13 | −$2.92 | — | $7.58 |
| 2023 | $0.10 | −$3.86 | $0.07 | −$3.17 | — | $11.09 |
| 2024 | $0.00 | −$3.58 | $0.06 | −$3.38 | — | $12.19 |
| 2025 | $0.00 | −$5.95 | $0.08 | −$4.81 | — | $8.28 |